Therefore, in this study, we aimed to identify which T cell modulating antibody combinations (α-CTLA-4, α-PD-1, α-CD137) could enhance the anti-tumor effect of SBRT in an inducible mouse model of human BRAFV600-mutant and PTEN-deficient melanoma [25, 26]. This evidence concerns the gene TNFRSF9 and neoplasm.